# Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer

> **NCT00216073** · PHASE2 · TERMINATED · sponsor: **Hoosier Cancer Research Network** · enrollment: 11 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT00216073
- **Lead sponsor:** Hoosier Cancer Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-03
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Lack of patient accrual
- **Last updated:** 2011-05-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216073, "Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00216073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*